Tocilizumab improves the efficacy of anti-PD-1 in a patient with advanced gastroesophageal junction cancer: a case report
BackgroundCancer-related inflammation contributes to the progression of malignancies and considerably affects therapeutic outcomes. IL-6 acts as a main mediator of both local and systemic inflammatory responses. Although IL-6 therapies have been successful in the treatment of inflammatory conditions...
Saved in:
| Main Authors: | Yushi Cai, Xuan Jin, Yun Dai |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-04-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1530387/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Dual efficacy of tocilizumab in managing PD-1 inhibitors-induced myocardial inflammatory injury and suppressing tumor growth with PD-1 inhibitors: a preclinical study
by: Yanxin Chen, et al.
Published: (2025-01-01) -
Tocilizumab in combination with corticosteroids: potential for managing cancer cachexia with systemic hyperinflammation
by: Ping Chen, et al.
Published: (2024-12-01) -
Efficacy of Tocilizumab in Patients with a Moderate and Severe COVID-19: A Retrospective Single Center Cohort Study
by: Sibel BOLUKÇU, et al.
Published: (2021-01-01) -
Influence of anti-Spike protein antibody levels on tocilizumab efficacy in hospitalized patients with severe COVID-19 pneumonia: a post-hoc analysis of the COVACTA trial
by: José Aguareles, et al.
Published: (2025-05-01) -
A spectacular effect of tocilizumab in Takayasu arteritis
by: Fatma Saïd, et al.
Published: (2024-11-01)